Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Effect of concomitant therapy on adynamic bone disease].

Y Kitabata1, T Akizawa

  • 1Center of Blood Purification Therapy, Wakayama Medical University.

Clinical Calcium
|March 19, 2005
PubMed
Summary

Parathyroid hormone (PTH) resistance in uremia causes adynamic bone disease. Correcting hypercalcemia by adjusting medications and dialysate calcium is key to increasing PTH secretion and managing bone disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low health-related quality of life is associated with all-cause mortality in patients with diabetes on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study.

Diabetic medicine : a journal of the British Diabetic Association·2009
Same author

Depressive symptoms predict the future risk of severe pruritus in haemodialysis patients: Japan Dialysis Outcomes and Practice Patterns Study.

The British journal of dermatology·2009
Same author

Diagnosing Alport syndrome using electron microscopy of the skin.

Kidney international·2008
Same author

Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study.

Diabetologia·2007
Same author

Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan.

Kidney international·2006
Same author

Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

Kidney international·2006

Area of Science:

  • Nephrology
  • Endocrinology
  • Bone Metabolism

Context:

  • Adynamic bone disease is a common complication in patients with chronic kidney disease (CKD) and uremia.
  • Parathyroid hormone (PTH) deficiency or resistance to PTH in uremia is considered the primary cause of adynamic bone disease.

Purpose:

  • To investigate the management strategies for increasing parathyroid hormone (PTH) secretion in uremic patients.
  • To highlight the importance of correcting hypercalcemia for improving PTH levels and bone health.

Summary:

  • Hypercalcemia in uremia contributes to PTH deficiency and skeletal resistance to PTH, leading to adynamic bone.
  • Management involves adjusting calcium-containing phosphate binders and active vitamin D sterols to prevent hypercalcemia.
  • Optimizing dialysate calcium concentration is crucial for stimulating PTH secretion.

Impact:

  • This approach aims to improve PTH secretion and potentially mitigate the progression of adynamic bone disease in uremic patients.
  • Findings guide therapeutic adjustments in CKD management to address bone and mineral disorders.

Related Experiment Videos